In vivo (Athens, Greece) · 2025
Spot Scanning Proton Beam Therapy for Surgery-inaccessible Hepatocellular Carcinoma: Preliminary Results.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Fujimoto Yutaka, Shiraishi Sachika, Yamanaka Masashi, Yamano Akihiro, Matsumoto Kazuki, Shiba Shintaro, Tsukiyama Toshitaka, Kobayashi Masahiro, Tokuuye Koichi
Аннотация
BACKGROUND/AIM: Spot scanning proton beam therapy (SS-PBT) was employed for the treatment of surgery-inaccessible hepatocellular carcinoma, primarily influenced by respiratory movement.
PATIENTS AND METHODS: Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
RESULTS: The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
CONCLUSION: SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.
PATIENTS AND METHODS: Between October 2022 and December 2023, 12 patients were enrolled in this study to evaluate the efficacy of SS-PBT. The median follow-up time was 13.1 months.
RESULTS: The one-year survival, progression-free survival, and local control rates were 79.5%, 57.1%, and 100%, respectively, without grade 2 or higher PBT-related toxicities. The clinical outcomes of these 12 patients appear comparable to data from prospective studies conducted at proton centers across Japan.
CONCLUSION: SS-PBT shows promise as a treatment option for surgery-inaccessible hepatocellular carcinoma.